AWM
REGN icon

AE Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

AE Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.16M Buy
6,681
+1,207
+22% +$924K 0.03% 413
2025
Q4 		$4.23M Buy
5,474
+1,470
+37% +$998K 0.02% 434
2025
Q3 		$2.25M Buy
4,004
+1,371
+52% +$775K 0.01% 536
2025
Q2 		$1.38M Buy
2,633
+408
+18% +$228K 0.01% 634
2025
Q1 		$1.41M Buy
2,225
+445
+25% +$306K 0.01% 622
2024
Q4 		$1.27M Buy
1,780
+706
+66% +$592K 0.01% 650
2024
Q3 		$1.13M Buy
1,074
+527
+96% +$586K 0.01% 668
2024
Q2 		$575K Buy
547
+89
+19% +$86.3K 0.01% 850
2024
Q1 		$441K Sell
458
-3,210
-88% -$3.05M 0.01% 855
2023
Q4 		$3.45M Buy
3,668
+2,450
+201% +$2.02M 0.02% 718
2023
Q3 		$1M Sell
1,218
-2,031
-63% -$1.6M 0.01% 1093
2023
Q2 		$2.33M Sell
3,249
-631
-16% -$487K 0.01% 800
2023
Q1 		$3.19M Sell
3,880
-677
-15% -$511K 0.02% 640
2022
Q4 		$3.29M Sell
4,557
-8,384
-65% -$6.19M 0.02% 589
2022
Q3 		$8.91M Buy
12,941
+82
+0.6% +$51.6K 0.07% 302
2022
Q2 		$7.6M Buy
12,859
+2,845
+28% +$1.85M 0.06% 334
2022
Q1 		$6.99M Buy
10,014
+176
+2% +$111K 0.05% 362
2021
Q4 		$6.21M Buy
9,838
+5,658
+135% +$3.48M 0.04% 377
2021
Q3 		$2.53M Sell
4,180
-169
-4% -$105K 0.02% 573
2021
Q2 		$2.43M Buy
4,349
+601
+16% +$304K 0.02% 575
2021
Q1 		$1.77M Buy
3,748
+3,044
+432% +$1.48M 0.02% 603
2020
Q4 		$340K Sell
704
-1,436
-67% -$775K ﹤0.01% 1091
2020
Q3 		$1.2M Buy
2,140
+236
+12% +$143K 0.02% 583
2020
Q2 		$1.19M Buy
1,904
+514
+37% +$292K 0.02% 566
2020
Q1 		$679K Buy
1,390
+808
+139% +$333K 0.02% 589
2019
Q4 		$219K Buy
+582
New +$196K ﹤0.01% 1035
2019
Q3 		– Sell
-705
Closed -$221K – 1055
2019
Q2 		$221K Buy
+705
New +$235K 0.01% 865
2018
Q1 		– Sell
-548
Closed -$206K – 467
2017
Q4 		$206K Buy
+548
New +$222K 0.02% 393

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

AE Wealth Management's REGN Position: Q1 2026 in Review

AE Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $924K and bringing the position to 6,681 shares worth $5.16M. The position accounts for 0.03% of the portfolio, ranked #413.

AE Wealth Management first reported a position in REGN in Q4 2017 and has held it in 28 quarters since. The position peaked at $8.91M in Q3 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • AE Wealth Management held 6,681 shares of Regeneron Pharmaceuticals worth $5.16M as of Q1 2026.
  • AE Wealth Management bought 1,207 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $924K.
  • Regeneron Pharmaceuticals made up 0.03% of AE Wealth Management's portfolio in Q1 2026, its #413 holding.
  • AE Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • AE Wealth Management's Regeneron Pharmaceuticals position peaked at $8.91M in Q3 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on AE Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.